Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis
- Status
- TERMINATED
- Phase
- PHASE2
Pan Tumor Rollover Study
- Status
- RECRUITING
- Phase
- PHASE2
Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma
- Status
- COMPLETED
- Phase
- PHASE2
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Status
- RECRUITING
- Phase
- PHASE2
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction
- Status
- UNKNOWN
- Phase
- PHASE1
Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1